Study to Prevent Dysglycemia in Women With GDM

NCT ID: NCT07269405

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-26

Study Completion Date

2030-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Women with a history of gestational diabetes mellitus (GDM) have a 7-fold increased risk of type 2 diabetes (T2D), with the risk at its highest during the 3-6 years postpartum. GDM thus represents one of the strongest known risk factors for T2D.

Only 30-60% of women with GDM returned for postpartum visits, with the majority defaulting on postpartum glucose tolerance testing. Women with GDM also have an increased risk of hypertension, cardiovascular disease (CVD), non-alcoholic fatty liver disease, and other comorbidities. Through this study, participants will receive lifestyle advice that may help them prevent diabetes. The study will help determine whether a multicomponent intervention will prevent incident dysglycemia and improve offspring cardiometabolic health. This will inform healthcare professionals and policymakers if these interventions are helpful. The control group will receive basic dietary information leaflets and will have access to the e-care platform for the three-year period (8-166 weeks postnatal). They will receive routine lifestyle advice and counseling. The intervention groups will receive information on basic dietary information and have access to the e-platform. Participants will attend individualized/group dietary counseling sessions biweekly in the first 4 months during the intensive phase (V1-V7) and thereafter bimonthly (V8-10, 28-50 weeks postnatal) and biyearly between year 1 to year 3. This will include 16 sessions with a dietitian/nutritionist and 4 sessions with an exercise instructor. Participants will be given an individualized menu plan aiming at achieving a varied, balanced diet with an emphasis on fiber intake and moderate-carbohydrate, low-fat, low-glycemic index products in appropriate portions. The lifestyle intervention program will incorporate motivational interviewing and behavioral modification to enhance health knowledge on daily diet and physical activity. The lifestyle intervention aims to achieve targets on body weight, dietary intake, and physical activities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The high-risk nature of women with GDM highlights this group as the "low-hanging fruit" who would substantially benefit from engagement in diabetes prevention programs. Lifestyle intervention has been shown to reduce the progression to T2D among women with GDM.

In a systematic review and meta-analysis including 8 lifestyle intervention trials implemented post-GDM, there was a homogenous 25% reduction (relative risk (RR): 0.75; 95% confidence interval (CI) 0.55-1.03) in incident diabetes, though not statistically significant. Of note, trials offering intervention soon after delivery (i.e., \<6 months postpartum) were most effective. This contrasts with efforts during pregnancy to reduce GDM, which have failed to reduce GDM unless initiated very early. The long-term follow-up of mothers and offspring from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study has highlighted the increased risk of adiposity, obesity, and diabetes in offspring, who are at increased risk of NCDs later in life. Hence, enrolling mothers with GDM in empowerment and prevention programs will not only reduce their risk of diabetes and CVD but may also benefit other family members, in particular the offspring.

In a previous pilot lifestyle intervention trial in mothers with GDM in the postpartum setting (NCT03669887), the investigators established the logistics of engaging mothers during the busy postpartum period, performing repeated OGTTs and clinical assessments, and co-designing with mothers a lifestyle intervention curriculum suitable for implementation during the postpartum period. The investigators demonstrated the benefit of the intervention in improving the health behaviors of GDM mothers at 1 year. The investigators were able to engage participants with GDM and noted their misconceptions about the long-term impact of GDM, their concerns about whether they can breastfeed, and lack of awareness of the risk of obesity in their offspring. The intervention arm had improved dietary quality as measured using the Dietary Quality Index-International (DQI-I) score, more favorable changes in BMI at 6 months postpartum, and a trend towards better glycemic status after 12 months.

Objectives:

Primary objective

\- To evaluate the effect of a multicomponent postpartum intervention to prevent incident dysglycemia in women with a history of GDM.

Secondary objectives"

* To evaluate the effect of a multicomponent intervention on body weight and composition.
* To evaluate the effect of a multicomponent intervention on cardiometabolic health parameters including blood pressure, heart rate, vital signs, and lipid profiles.
* To evaluate the effect of a multicomponent intervention on continuous glucose monitoring metrics.
* To evaluate the effect of a multicomponent intervention on dietary intake.
* To evaluate the effect of a multicomponent intervention on physical activity.
* To evaluate the effect of a multicomponent intervention on breastfeeding and infant feeding practices.
* To evaluate the effect of a multicomponent intervention on offspring growth, weight, and adiposity.

Compared with conventional care.

Study design: Multi-center, prospective, parallel-group, open-label randomized controlled trial Study population: Women with a history of GDM Sample size: 800 subjects Intervention: Multicomponent intervention including e-care and wearables Comparator: Conventional care

Setting:

Women with a history of gestational diabetes will be identified from antenatal clinics. The study will be conducted at the Prince of Wales Hospital and the CUHK Medical Centre.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gestatiaonl Diabetes Mellitus GDM

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Gestatiaonl diabetes mellitus GDM Postpartum Lifestyle intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Multi-component lifestyle intervention
Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors
Data analysts

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multicomponent Lifestyle Intervention

Multicomponent intervention include e-care and wearables

Group Type EXPERIMENTAL

Intervention

Intervention Type BEHAVIORAL

The intervention groups will receive information on basic dietary information and have access to e-platform.

Participants will attend individualised/ group dietary counselling sessions biweekly in the first 4 months during the intensive phase and thereafter bimonthly and biyearly between year 1 to year 3.

This will include 16 sessions with a dietitian/nutritionist and 4 sessions with an exercise instructor. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fibre intake and moderate-carbohydrate, low-fat, low-glycaemic index products in appropriate portions.

Conventional Care

Conventional care

Group Type OTHER

Conventional care

Intervention Type OTHER

The control group will receive basic dietary information leaflets and will have access to the e-care platform for the three-year period. The control group will receive routine lifestyle advice.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intervention

The intervention groups will receive information on basic dietary information and have access to e-platform.

Participants will attend individualised/ group dietary counselling sessions biweekly in the first 4 months during the intensive phase and thereafter bimonthly and biyearly between year 1 to year 3.

This will include 16 sessions with a dietitian/nutritionist and 4 sessions with an exercise instructor. Participants will be given an individualized menu plan aiming at achieving a varied balanced diet with an emphasis on fibre intake and moderate-carbohydrate, low-fat, low-glycaemic index products in appropriate portions.

Intervention Type BEHAVIORAL

Conventional care

The control group will receive basic dietary information leaflets and will have access to the e-care platform for the three-year period. The control group will receive routine lifestyle advice.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women with a history of gestational diabetes mellitus and one additional risk factor (obesity, family history of diabetes, impaired fasting glycemia and/or impaired glucose tolerance and/ and or risk understanding by yourself RUBY score of ≥ 8) at 6-12 weeks postpartum
2. Singleton pregnancy
3. Willingness, ability and commitment to comply with study procedures
4. In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a suitable study candidate.
5. Normally residing in Hong Kong
6. Able to communicate in Chinese
7. Written informed consent to participate in the study provided by the patient

Exclusion Criteria

1. Known current diabetes
2. Current or previous use of glucose-lowering or weight loss drugs at screening
3. Concurrent participation in other weight loss or lifestyle intervention programmes
4. Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study
5. Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff
6. Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device
7. Known uncontrolled thyrotoxicosis
8. Current use of steroids
9. Known current or recent alcohol or drug abuse
10. Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection
11. An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner)
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Professor Ronald C.W. Ma

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital

Shatin, , Hong Kong

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025.127

Identifier Type: -

Identifier Source: org_study_id